The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
New HCV drug treatments are now primarily focusing on inhibiting Hepatitis C viral replication by targeting a particular viral protein. Based on preliminary clinical findings, one treatment option in development has been discontinued, in favor of another lead contender as a breakthrough Hepatitis C treatment.
Continue reading »The goal of those currently undergoing treatment for chronic Hepatitis C is to prevent further liver damage from the Hepatitis C virus. Read this exclusive article to learn how to incorporate antioxidants into your lifestyle. Here is a simple, reputable and reasonably priced way to support your liver.
Continue reading »Marked by less frequent dosing, higher patient compliance and reduced side effects, OctoPlus Pharmaceuticals is now in Phase IIa testing with LocteronTM. A controlled release version of alfa-interferon, Locteron may end up being the preferred medical treatment for Hepatitis C.
Continue reading »Two pharmaceutical companies are taking a similar approach in helping those facing acute liver failure. Recognizing both the ability of healthy liver cells to replicate and the difficulties involved in liver transplantation, the collaboration between Vesta and Cytonet is based on transplanting healthy liver cells to those in need.
Continue reading »A new culture method greatly improves researchers' ability to study the Hepatitis C virus. Experts believe this breakthrough may enhance our knowledge of HCV, eventually contributing to enhanced treatment options.
Continue reading »A Stanford University discovery has identified certain proteins as necessary components for Hepatitis C virus replication. Presidio Pharmaceuticals has licensed the rights to use this information for developing a Hepatitis C treatment that prevents drug resistance, the leading cause of viral eradication failure.
Continue reading »Although the connection remains tentative, Hepatitis C patients who have received a liver transplant and are taking the post-transplant drug, Prograf, may be at higher risk for developing type 2 diabetes.
Continue reading »Utilizing Chinese medicine's long history of safe and therapeutic use, a pharmaceutical company has developed a drug derived from botanicals to treat Hepatitis C symptoms. Now that it has received FDA approval to begin clinical trials, this unique approach may become a new treatment option for Hepatitis C patients.
Continue reading »The 20-year patent on pegylated interferon is up, allowing an Indian pharmaceutical company to devise and offer an effective medication at a fraction of the cost of the current treatment. The long-time hope of HCV patients of an affordable Hepatitis C treatment may soon be realized.
Continue reading »Recent research has uncovered a racial disparity in regard to fat accumulation in the livers of Hepatitis C patients. The same research also indicates that levels of insulin resistance vary among races. This discovery may prove beneficial to HCV patients if modifications to insulin resistance factors lead to controlling the progression of a fatty liver.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
